Lv1
40 积分 2022-06-14 加入
Resistance looms for KRAS G12C inhibitors and rational tackling strategies
30天前
已完结
Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study
2个月前
已完结
Development of the cancer therapy satisfaction questionnaire: item generation and content validity testing
2个月前
已完结
Randomised crossover trial to assess the tolerability of LHRH analogue administration
2个月前
已完结
Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel disease
2个月前
已完结
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab
3个月前
已完结
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
3个月前
已完结
恶性胸腔积液治疗的中国专家共识（2023年版）
3个月前
已完结
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
4个月前
已完结
皖公网安备34019202002308
